Floatz logo

Ppsv23

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Region Örebro CountyvaccinePhase 4 / ApprovedDormant
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
89/ 100

Competitive context

203 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
Etoposide
Weill Medical College of Cornell University
Phase 2BBB
Chlorambucil
Ascentage Pharma Group Inc.
Phase 4BBB
Lisaftoclax
Henan Cancer Hospital
Phase 3BBB
Prednisone
AstraZeneca
Phase 3BBB
Irinotecan
IGM Biosciences, Inc.
Phase 2BBB

View all 50 →

Same molecule, other indications

Ppsv23 is also rated in:

pneumococcal infectionActive
BB
Indicative · Phase 4
69 / 100
View asset →
thalassemiaDormant
BB
Indicative · Phase 4
68 / 100
View asset →
relapsing-remitting multiple sclerosisActive
B
Indicative · Phase 3
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →